Erasmus Medical Center, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
Trans R Soc Trop Med Hyg. 2021 Apr 14;115(4):343-354. doi: 10.1093/trstmh/traa184.
Eumycetoma is a neglected tropical implantation mycosis characterized by large subcutaneous swellings. Inside the infected tissue, the causative agents are found in grains. The most common causative agents form black grains and are sterile upon isolation. In vitro susceptibility assays were developed for eumycetoma causative agents. They were based on the Clinical and Laboratory Standards Institute M38A protocol and modified to enable the use of hyphae as a starting inoculum. To ease endpoint reading, viability dyes such as resazurin or XTT have been used. So far the in vitro susceptibility assays developed have mainly been used to establish if causative agents are inhibited in growth by various antifungal agents, but not for clinical decision making. For drug discovery, the assay proved useful in determining which compounds were able to prevent hyphal growth. However, a clear correlation between in vitro inhibition in terms of the half maximal inhibitory concentration or 50% minimum inhibitory concentration (MIC50) and therapeutic efficacy assayed in a novel model system in terms of Galleria mellonella larval survival was not found. For clinical decision making, a range of MICs were found for each antifungal agent. However, no clinical breakpoints have been established for any of the causative agents. For itraconazole, the MIC50 of most causative agents was below the attainable serum levels, which might indicate that they are susceptible. However, before in vitro susceptibility can be used in clinical decision making for mycetoma, a correlation between MIC and clinical outcome needs to be made.
芽生菌病是一种被忽视的热带植入性真菌病,其特征为皮下出现大的肿胀。在受感染的组织内,病原体以颗粒的形式存在。最常见的病原体形成黑色颗粒,在分离时无菌。已为芽生菌病病原体开发了体外药敏检测方法。这些方法基于临床和实验室标准协会 M38A 方案,并进行了修改,以便能够使用菌丝作为起始接种物。为了便于终点读取,已使用了诸如 Resazurin 或 XTT 等生存力染料。到目前为止,开发的体外药敏检测方法主要用于确定各种抗真菌药物是否能抑制病原体的生长,但不能用于临床决策。对于药物发现,该检测方法有助于确定哪些化合物能够防止菌丝生长。然而,在新型模型系统中,以半最大抑制浓度(IC50)或 50%最小抑制浓度(MIC50)的体外抑制与以 Galleria mellonella 幼虫存活率表示的治疗效果之间并未发现明确的相关性。对于临床决策,对于每种抗真菌药物,都发现了一系列 MIC。然而,尚未为任何病原体建立任何临床折点。对于伊曲康唑,大多数病原体的 MIC50 均低于可达到的血清水平,这可能表明它们具有敏感性。然而,在将体外药敏用于芽生菌病的临床决策之前,需要建立 MIC 与临床结果之间的相关性。